CM
ALNY icon

Capula Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Capula Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.34M Sell
13,115
-66
-0.5% -$22.5K 0.03% 140
2025
Q4 		$5.24M Buy
13,181
+6,293
+91% +$2.79M 0.03% 149
2025
Q3 		$3.14M Buy
+6,888
New +$2.8M 0.02% 197
2024
Q1 		– Sell
-5,270
Closed -$1.01M – 469
2023
Q4 		$1.01M Buy
+5,270
New +$898K 0.04% 100

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capula Management's ALNY Position: Q1 2026 in Review

Capula Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.5% in Q1 2026, selling an estimated $22.5K and leaving 13,115 shares worth $4.34M. The position accounts for 0.03% of the portfolio, ranked #140.

Capula Management first reported a position in ALNY in Q4 2023 and has held it in 4 quarters since. The position peaked at $5.24M in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Capula Management held 13,115 shares of Alnylam Pharmaceuticals worth $4.34M as of Q1 2026.
  • Capula Management sold 66 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $22.5K.
  • Alnylam Pharmaceuticals made up 0.03% of Capula Management's portfolio in Q1 2026, its #140 holding.
  • Capula Management first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 4 quarters since.
  • Capula Management's Alnylam Pharmaceuticals position peaked at $5.24M in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Capula Management's 13F filing for Q1 2026, filed 14 May 2026.